Camp4 Therapeutics Poration Stock Beta
| CAMP Stock | USD 5.46 0.18 3.41% |
CAMP4 THERAPEUTICS PORATION fundamentals help investors to digest information that contributes to CAMP4 THERAPEUTICS's financial success or failures. It also enables traders to predict the movement of CAMP4 Stock. The fundamental analysis module provides a way to measure CAMP4 THERAPEUTICS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CAMP4 THERAPEUTICS stock.
CAMP4 |
CAMP4 THERAPEUTICS PORATION Company Beta Analysis
CAMP4 THERAPEUTICS's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current CAMP4 THERAPEUTICS Beta | 1.89 |
Most of CAMP4 THERAPEUTICS's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CAMP4 THERAPEUTICS PORATION is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, CAMP4 THERAPEUTICS PORATION has a Beta of 1.886. This is 77.92% higher than that of the Communications Equipment sector and 40.32% lower than that of the Information Technology industry. The beta for all United States stocks is notably lower than that of the firm.
CAMP4 Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CAMP4 THERAPEUTICS's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CAMP4 THERAPEUTICS could also be used in its relative valuation, which is a method of valuing CAMP4 THERAPEUTICS by comparing valuation metrics of similar companies.CAMP4 THERAPEUTICS is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CAMP4 THERAPEUTICS will likely underperform.
CAMP4 Fundamentals
| Current Valuation | 109.74 M | ||||
| Shares Outstanding | 20.16 M | ||||
| Shares Owned By Insiders | 35.40 % | ||||
| Shares Owned By Institutions | 56.95 % | ||||
| Number Of Shares Shorted | 359.72 K | ||||
| Price To Earning | 318.57 X | ||||
| Revenue | 186.23 M | ||||
| Gross Profit | (37.93 M) | ||||
| EBITDA | (8.72 M) | ||||
| Net Income | (49.29 M) | ||||
| Cash And Equivalents | 47.72 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 178.68 M | ||||
| Current Ratio | 1.86 X | ||||
| Book Value Per Share | (158.04) X | ||||
| Cash Flow From Operations | (44.16 M) | ||||
| Short Ratio | 3.48 X | ||||
| Earnings Per Share | (2.64) X | ||||
| Price To Earnings To Growth | 0.08 X | ||||
| Target Price | 19.91 | ||||
| Number Of Employees | 53 | ||||
| Beta | 1.89 | ||||
| Market Capitalization | 102.82 M | ||||
| Total Asset | 54.95 M | ||||
| Retained Earnings | (159.96 M) | ||||
| Working Capital | 32.21 M | ||||
| Current Asset | 298.77 M | ||||
| Current Liabilities | 49.56 M | ||||
| Net Asset | 54.95 M |
About CAMP4 THERAPEUTICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CAMP4 THERAPEUTICS PORATION's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CAMP4 THERAPEUTICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CAMP4 THERAPEUTICS PORATION based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for CAMP4 Stock Analysis
When running CAMP4 THERAPEUTICS's price analysis, check to measure CAMP4 THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CAMP4 THERAPEUTICS is operating at the current time. Most of CAMP4 THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of CAMP4 THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CAMP4 THERAPEUTICS's price. Additionally, you may evaluate how the addition of CAMP4 THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.